RE:News DumpSome early standouts... “With the investment in iDialco, Spectral is no longer focused on the dialysis device market, and therefore the Dialco operations were considered discontinued as at December 31, 2022.”
“It was difficult to accurately budget for the cost of completing the DIMI Trial, but Spectral expected costs to exceed $10,000. In order to pursue and complete the DIMI Trial, external funds would have been required.”
“With Spectral being unable to secure financing to support the DIMI Trial, on December 12, 2022, Spectral negotiated and entered into the joint arrangement with Infomed SA”
The outline of Spectral’s last raise clearly stated that they would not use any of the funds raised for Dialco. Now they are saying they couldn’t support the trial because they couldn’t raise funds.
So they cut off the money from the trial- and are now blaming the raise?
-I see no mention of the contract obligation with Infomed that Spectral missed in June- the issue that suddenly caused the licensing agreement to be only until Nov 30th 2022. They are clearly trying to remove that information from the record- even
-Zero mention of Sam Amory in the MD&A. so I guess he wasn’t hired as a President or let go.